Ac­celeron drops a de­vel­op­ment pro­gram as #2 drug fails to spark func­tion­al ben­e­fits in pa­tients with a rare neu­ro­mus­cu­lar ail­ment

Ac­celeron is scrap­ping a mus­cu­lar dy­s­tro­phy de­vel­op­ment pro­gram un­der­way for its num­ber 2 drug in the pipeline af­ter pour­ing over some failed mid-stage sec­ondary da­ta.

Gone is the ACE-083 project in pa­tients with fa­cioscapu­lo­humer­al mus­cu­lar dy­s­tro­phy. Their drug hit the pri­ma­ry end­point on build­ing mus­cle but flopped on key sec­on­daries for func­tion­al im­prove­ments in pa­tients, which ex­ecs felt was vi­tal to the drug’s suc­cess.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER